You are here: Industry Insights > LAAB

News List

Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment worldpharmanews
March 22, 2021
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
AstraZeneca to supply 500,000 doses of Covid-19 antibody to the US pharmaceutical-technology
March 18, 2021
AstraZeneca (AZ) has signed an agreement with the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) for the supply of up to 500,000 additional doses of its Covid-19 antibody treatment for $205m.
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials worldpharmanews
October 14, 2020
AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the this weeks.
AstraZeneca secures $486m from US for Covid-19 antibody pharmaceutical-technology
October 14, 2020
AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment.